Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Liabilities (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Total Liabilities data on record, last reported at $465.1 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 6.5% year-over-year to $465.1 million; the TTM value through Dec 2025 reached $465.1 million, up 6.5%, while the annual FY2025 figure was $465.1 million, 6.5% up from the prior year.
  • Total Liabilities reached $465.1 million in Q4 2025 per SNDX's latest filing, up from $436.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $465.1 million in Q4 2025 and bottomed at $21.6 million in Q3 2022.
  • Average Total Liabilities over 5 years is $141.8 million, with a median of $48.1 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: tumbled 48.98% in 2023, then skyrocketed 929.65% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $41.3 million in 2021, then fell by 27.86% to $29.8 million in 2022, then soared by 97.01% to $58.7 million in 2023, then soared by 644.14% to $436.7 million in 2024, then increased by 6.5% to $465.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $465.1 million in Q4 2025, $436.4 million in Q3 2025, and $438.7 million in Q2 2025.